Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
Search results for: hospital
FDA Proposal for Biosimilar Use in 2025 Budget
A proposal for biosimilar use in the 2025 budget would allow substitution of any biosimilar for its reference product without an interchangeable designation. The hope is to increase biosimilar uptake, with the subsequent potential to increase product “competition, access and affordability.”1 In the 2025 budget proposal, the Biden administration noted that the legal distinction between…
The Biases We Don’t Know We Hold
Implicit bias can affect patient care at the physician level when they’re making treatment decisions and at the healthcare organization level when they’re choosing new hires. Here are insights into strategies rheumatologists can use to become aware of, and question, their implicit biases.
Mental Health in Rheumatology
Regaining a sense of control, limiting responsibilities and engaging in mindfulness can help rheumatologists manage their mental health needs. Rheumatologists should also address the mental health concerns raised by their patients. Here are insights from a psychiatrist/rheumatologist.
Interferons in Systemic Lupus Erythematosus
Current knowledge of receptor-ligand interactions, cell signaling, and transcriptional regulation derive from studies of type I interferon. The design of novel therapeutics is informed by the advances in investigation of type I interferon, with the potential for important impacts on patient management.
Focus on Community Practice Rheumatology
Community practice rheumatology brings with it certain challenges, but it also offers rewards, such as autonomy and the capacity to develop deep relationships with patients. Three rheumatologists discuss the challenges and rewards of private practice.
Congressional Action Partially Addresses Medicare Cuts
The newest funding package reduces the latest cut to Medicare reimbursement from 3.4% to 1.68%. Although rheumatologists are faring better under Medicare in 2024, broader reforms remain the ACR’s highest priority regarding Medicare payments to physicians.
Sharad Lakhanpal, MBBS, MD, Named an APLAR Master
In early December, Sharad Lakhanpal, MBBS, MD, a rheumatologist at Rheumatology Associates in Dallas and past president of the ACR, traveled to Chiang Mai, Thailand, for the 2023 Congress of the Asia Pacific League of Associations for Rheumatology (APLAR). There he was named an APLAR Master. The award is presented to someone not from APLAR,…
The Roles of the Interdisciplinary Rheumatology Team in Patient Care Highlighted
To work together effectively, clinicians and rheumatology professionals need to understand the roles of every member of the interdisciplinary team. To enhance this understanding, the ARP Interprofessional Practice & Management Committee has undertaken a project to describe the modern roles of members of the interdisciplinary team in a series of fact sheets. The first three…
Can Repeat Injections Improve Knee OA Pain?
Promising Results from a Phase 3 Study SAN DIEGO—An investigational liposomal formulation of dexamethasone sodium phosphate (TLC599) for intra-articular injection is being studied to treat patients with knee osteoarthritis (OA). George Spencer-Green, MD, MS, chief medical officer of Taiwan Liposome Company (TLC), Cambridge, Mass., presented recent data on this agent in a late-breaking abstract session…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 323
- Next Page »